What is the percentage of hair loss associated with Fosamax (alendronate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hair Loss with Fosamax (Alendronate)

Hair loss is not a documented adverse effect of Fosamax (alendronate) based on available clinical trial data and systematic reviews.

Evidence from Clinical Trials

The extensive clinical trial experience with alendronate does not identify hair loss as an adverse event:

  • Large-scale trials in postmenopausal women involving over 10,000 participants in primary prevention studies and over 7,000 in secondary prevention studies did not report hair loss as an adverse event 1

  • Studies in men with osteoporosis (241 participants over two years) documented upper gastrointestinal effects and musculoskeletal pain as the primary adverse events, with no mention of alopecia 2

  • Glucocorticoid-induced osteoporosis trials (477 participants over 48 weeks) reported only nonserious upper gastrointestinal effects as the main tolerability concern, without documenting hair loss 3

Documented Adverse Event Profile

The established adverse events associated with alendronate include:

  • Upper gastrointestinal tract effects are the most common, including abdominal pain, nausea, dyspepsia, and acid regurgitation 4

  • Musculoskeletal pain occurs but shows no statistically significant difference from placebo in large trials 4

  • Serious adverse events show no clinically important increase compared to placebo (relative risk 1.08 in primary prevention, 0.75 in secondary prevention) 1

Clinical Context

The provided evidence extensively discusses hair loss in the context of other medications (particularly acitretin, where hair loss occurs in up to 75% of patients) 5, but none of the alendronate-specific studies or systematic reviews document alopecia as an adverse effect 4, 6, 2, 1, 3.

Important Caveats

  • Postmarketing surveillance has identified rare esophageal adverse events not detected in clinical trials, suggesting that very rare effects may exist 4

  • If a patient reports hair loss while taking alendronate, alternative causes should be investigated including thyroid dysfunction, nutritional deficiencies, autoimmune conditions, or other medications 7

  • The absence of reported hair loss in clinical trials involving thousands of patients over multiple years provides strong evidence against a causal relationship 1

References

Research

Alendronate for the treatment of osteoporosis in men.

The New England journal of medicine, 2000

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.

Canadian family physician Medecin de famille canadien, 1998

Guideline

Initial Workup for Hair Loss

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.